Drug metabolism and apoptosis in HEPG2 cell line

Rustam, Samir
The liver is the principal site of drug metabolism. Drugs and other chemicals are all metabolized in the liver through the drug-metabolizing enzyme system. Metabolized drugs can have an effect on one another through crosstalk between drug metabolism pathways. Herbs used in folk and mainstream medicine, when taken together with drugs, can affect the rate at which drugs are processed by the liver. Salvia species are one of many herbal remedies which can be used together with prescribed drugs as part of alternative traditional medicine. Therefore, it is important to learn the effects of Salvia extracts on drug metabolism, and how it affects the metabolism of other drugs and their therapeutic ability when consumed together. Previously, we have characterized the water and methanol extracts of a Salvia species, S. absconditiflora, in our lab. In this study, we examine the effects of these extracts on gene expression of phase I and phase II enzymes by using quantitative real-time PCR panel microplates containing primers targeting these enzyme gene transcripts, and also further investigate the effects of S. absconditiflora extracts on ROS generation and the expression of genes associated with apoptosis. Web based Kyoto Encyclopedia of Genes and Genomes (KEGG) database was used for the analysis of pathway panel results. Analysis of changes in the metabolism pathways in response to S. absconditiflora extracts have revealed important ramifications for the metabolism of carcinogens and drugs involved in cancer therapy. S. absconditiflora extracts alter expression of key enzymes involved in the metabolism of carcinogens. Extracts also demonstrated the ability to affect potency and effectiveness of co-administered drugs. Further, the decrease in expression of key genes involved in apoptosis and the upregulation of genes associated with necrosis showed that inhibition of cell proliferation due to treatment is achieved by the induction of necrosis in HepG2 cells. 


Drug repositioning as an effective therapy for protease-activated receptor 2 inhibition
Saqib, Uzma; Savai, Rajkumar; Liu, DongFang; Banerjee, Sreeparna; Baig, Mirza S. (Wiley, 2019-02-01)
Proteinase-activated receptor 2 (PAR-2) is a G protein-coupled receptor activated by both trypsin and a specific agonist peptide, SLIGKV-NH2. It has been linked to various pathologies, including pain and inflammation. Several peptide and peptidomimetic agonizts for PAR-2 have been developed exhibiting high potency and efficacy. However, the number of PAR-2 antagonists is smaller. We screened the Food and Drug Administration library of approved compounds to retrieve novel antagonists for repositioning in the...
Downregulation of Programmed Cell Death 10 (PDCD 10) Expression Confers Doxorubicin Resistance in Breast Cancer Cells
Mamatoğlu, Çağrı Urfalı; Kazan, Hasan Hüseyin; Gündüz, Ufuk (null; 2017-10-08)
Dysregulated apoptosis is one of the major drug resistance mechanisms. Programmed cell death 10 (PDCD10) is a novel apoptosis regulator, involving in modulation of apoptosis and cell survival. Despite its importance in apoptotic regulation, the role of PDCD10 in drug resistance has not been understood yet. We screened parental and doxorubicin-resistant MCF7, HeLa and K562 cells for PDCD10 expression. Our results showed that PDCD10 expression is cell-specific; significantly downregulated in MCF7 and upregula...
Interaction of the cholesterol reducing agent simvastatin with zwitterionic DPPC and charged DPPG phospholipid membranes
Sariisik, Ediz; KOÇAK, MUSTAFA; Baloglu, Fatma Kucuk; Severcan, Feride (Elsevier BV, 2019-04-01)
Simvastatin is a lipid-lowering drug in the pharmaceutical group statins. Interaction of a drug with lipids may define its role in the system and be critical for its pharmacological activity. We examined the interactions of simvastatin with zwitterionic dipalmitoyl phosphatidylcholine (DPPC) and anionic dipalmitoyl phosphatidylglycerol (DPPG) multilamellar vesicles (MLVs) as a function of temperature at different simvastatin concentrations using Fourier transform infrared (FTIR) spectroscopy and differentia...
Drug Resistant MCF-7 Cell Lines Also Developed Cross-Resistance to Structurally Unrelated Anticancer Agents
Iseri, Ozlem D.; Kars, Meltem D.; Eroglu, Seckin; Gündüz, Ufuk (2009-03-01)
The cells developing resistance to an applied drug may also present cross-resistance to other anticancer drugs which are not applied. In this study, the development of cross-resistance in paclitaxel (MCF-7/Pac), docetaxel (MCF-7/Doc), vincristine (MCF-7/Vinc) and doxorubicin (MCF-7/Dox) resistant MCF-7 cells to selective anticancer drugs, tamoxifen and all trans-retinoic acid (ATRA) were investigated. Combined antiproliferative effects of these drugs in different combinations were also evaluated by checkerb...
Anticancer activity of chlorpromazine on U266 multiple myeloma cell line
Güleç, Aliye Ezgi; Özen, Can; Özçubukçu, Salih; Department of Biochemistry (2017)
Multiple Myeloma (MM) is the second most common hematological malignancy caused by malignant growth of plasma B cells. It accounts for 10% of deaths from blood cancers. Although introduction of new drugs has significantly increased the success of chemotherapy, MM remains as an incurable disease with a high relapse rate. Drug repositioning, finding new uses for approved drugs, is a frequently used strategy for the discovery of new chemotherapeutic agents. Since already approved drugs are used, the cost and t...
Citation Formats
S. Rustam, “Drug metabolism and apoptosis in HEPG2 cell line,” M.S. - Master of Science, Middle East Technical University, 2017.